Fortfahren mit
Anmelden zur Ansicht der Organisations- und Vertragspreise.
Größe auswählen
Ansicht ändern
| Ihnen/SKU | Verfügbarkeit | Preis |
|---|---|---|
10 mg | Warenkorb auf Verfügbarkeit prüfen | CHF 76.10 CHF 64.68 |
50 mg | Warenkorb auf Verfügbarkeit prüfen | CHF 329.00 |
Über diesen Artikel
Empirische Formel (Hill-System):
C20H24N2O6
CAS-Nummer:
Molekulargewicht:
388.41
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
264-407-7
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
CHF 64.68
ListenpreisCHF 76.10Sparen Sie 15%Aktion nur im Web
Warenkorb auf Verfügbarkeit prüfen
Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhaltenassay
≥98% (HPLC)
form
powder
color
yellow
solubility
DMSO: >10 mg/mL
originator
Bayer
storage temp.
room temp
SMILES string
COC(=O)C1=C(C)NC(C)=C(C1c2ccccc2[N+]([O-])=O)C(=O)OCC(C)C
InChI
1S/C20H24N2O6/c1-11(2)10-28-20(24)17-13(4)21-12(3)16(19(23)27-5)18(17)14-8-6-7-9-15(14)22(25)26/h6-9,11,18,21H,10H2,1-5H3
InChI key
VKQFCGNPDRICFG-UHFFFAOYSA-N
Gene Information
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
Application
Nisoldipine has been used:
- as a hit-antagonist to study its effects on oxytocin (OT)-induced myometrial Ca2+-mobilization and its potency to dampen uterine myometrial contractions
- as a calcium channel blocker to study its effects on cell viability in a human hepatic cancer HepG2 and rat renal epithelial NRK52E cell line
- as a component of the external IK1 recording solution to study the action potential in human pluripotent stem cell−derived cardiomyocytes (hiPS-CMs)
Biochem/physiol Actions
L-type (CaV1.2) calcium channel blocker; dihydropyridine-type calcium channel blocker with selectivity for smooth muscle (CaV1.2b) over cardiac muscle (CaV1.2a). Arterial vasodilator and antihypertensive agent.
Features and Benefits
This compound is featured on the Calcium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bayer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| assay ≥98% (HPLC) | assay ≥98% | assay - | assay - |
| form powder | form powder | form - | form - |
| Quality Level 100 | Quality Level 100 | Quality Level - | Quality Level 300 |
| storage temp. room temp | storage temp. 2-8°C | storage temp. - | storage temp. 2-30°C |
| solubility DMSO: >10 mg/mL | solubility DMSO: ~1 mg/mL, 0.1 M NaOH: insoluble, H2O: slightly soluble, methanol: soluble | solubility - | solubility - |
| color yellow | color yellow | color - | color - |
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
Lagerklasse
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.



